Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
11.05
+0.63 (6.05%)
At close: Jan 22, 2026, 4:00 PM EST
11.01
-0.04 (-0.36%)
After-hours: Jan 22, 2026, 6:29 PM EST
Fulcrum Therapeutics Employees
Fulcrum Therapeutics had 45 employees as of December 31, 2024. The number of employees decreased by 31 or -40.79% compared to the previous year.
Employees
45
Change (1Y)
-31
Growth (1Y)
-40.79%
Revenue / Employee
n/a
Profits / Employee
-$1,580,311
Market Cap
728.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 45 | -31 | -40.79% |
| Dec 31, 2023 | 76 | -13 | -14.61% |
| Dec 31, 2022 | 89 | -15 | -14.42% |
| Dec 31, 2021 | 104 | 31 | 42.47% |
| Dec 31, 2020 | 73 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 579 |
| MeiraGTx Holdings | 381 |
| Kura Oncology | 192 |
| Rigel Pharmaceuticals | 164 |
| Cullinan Therapeutics | 111 |
| enGene Holdings | 82 |
| Astria Therapeutics | 78 |
| Nektar Therapeutics | 61 |
FULC News
- 8 days ago - Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results - Benzinga
- 6 weeks ago - Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript - Seeking Alpha
- 6 weeks ago - Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - GlobeNewsWire